Viewpoints

With economics and politics in the way, can we defeat the malaria epidemic before it defeats us?

Operators are hit hard by breakage problems and strike out on FDA inspections.

Are hypersanitation trends a result of scaremongering or a lack of faith in medicine?

Patent pressures, changing disease profiles, and higher costs force companies to fight for the top.

Agents report unusual chemistry, abnormal data analysis, and unconventional work practices.

Legislative decisions to increase Medicare's formulary may lead to a fight over drug approvals.

The year 2011 may seem far off, but there is much to do to prepare for electronic pedigrees.

They may have seemed harmless at first, but these ideas took a big bite.

With no economic relief in sight, industry, like all of us, is grappling with high-and new-costs.

Customers complaining lead to some serious explaining.

Risk management, and its benefits for patients, plays a big role at the PDA Annual Meeting.

Letting the public inside the drug development process may increase their faith in what we do.

The good, the bad, and the ugly about direct-to-consumer advertising.

Scientists are giving up on a preventive vaccine for AIDS, but there are lessons to be learned.

Getting IT, engineering, and manufacturing on the same page requires a delicate balance.

WFI system deficiencies and damp tax records cause problems for two plants

Essential components of a good inspection: good ingredients, proper inserts, and ... deer?

The FDA itself issues a cry for help. Is anybody listening?

Was FDA's decision to issue a draft guidance on of-label information, amidst Congressional scrutiny, the right thing to do?

After two centuries, there's no reason to maintain two tablet compression tooling standards.

If not properly monitored, filters and plastic bags can keep back more than they should.

Show blasts off this month in Philadelphia with more suppliers, new trends, and real-world solutions.

The author suggests a route for nanotechnology's future in the pharmaceutical industry.

Can an overload of patent applications lead to the US' demise as a scientific leader?

If at first the product fails, then inspect, inspect again

With 2007 projects wrapped up, or so we hope, forward-looking companies need to take their next step.

Fixing FDA lies in the hands of the government, but is the president-to-be paying attention?

Process efficiency is measured not only by what is kept, but also by what is thrown away.

In honor of Pharmaceutical Technology's 30th anniversary, the editors conducted a survey of 320 readers last spring to discuss industry advances and future directions. Here are some of your foward-looking responses.

Drug makers, drug inspectors, and drug consumers need to demand that new drugs be effective.